Nanoparticle formulations for in situ construction of car t cells
By selectively delivering mRNA encapsulated in lipid nanoparticles to spleen cells, in situ generation of CAR T cells was achieved, solving the problems of complex production and high cost in existing technologies, and realizing safe and rapid CAR T cell therapy.
CN122161587APending Publication Date: 2026-06-05BOARD OF RGT THE UNIV OF TEXAS SYST
Patent Information
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- BOARD OF RGT THE UNIV OF TEXAS SYST
- Filing Date
- 2024-08-23
- Publication Date
- 2026-06-05
AI Technical Summary
Technical Problem
Existing CAR T-cell therapies are complex and costly to produce, making large-scale production impossible, and require ex vivo engineering, which makes it difficult for patients to receive timely treatment.
Method used
Lipid nanoparticles are used to encapsulate mRNA and selectively deliver it into spleen cells to achieve in situ generation of CAR T cells. The lipid nanoparticles are administered to the patient via intravenous injection to directly generate CAR T cells in vivo.
Benefits of technology
It enables the safe and rapid generation of CAR T cells in vivo, reducing tumor burden, prolonging patient survival, reducing liver metastases, simplifying the production process, and lowering costs.
✦ Generated by Eureka AI based on patent content.
Smart Images
Figure CN122161587A_ABST
Abstract
The present disclosure provides, in certain aspects, methods of generating CAR T cells in situ. The present disclosure provides lipid nanoparticles that selectively target splenocytes, particularly lymphocytes, such as T cells. The lipid nanoparticles provided herein include a five-component composition that includes a permanently anionic lipid, which renders the apparent pKa of the lipid nanoparticle less than 6.
Need to check novelty before this filing date? Find Prior Art